{"Clinical Trial ID": "NCT01151046", "Intervention": ["INTERVENTION 1:", "MM-121 + Exemestane", "MM-121 (40 mg/kg loading dose week 1, then 20 mg/kg per week) administered for 60 minutes as an intravenous infusion once a week plus exemestane (25 mg) administered orally once a day", "INTERVENTION 2:", "Placebo + Exemestane", "Placebo and Exemestane: Placebo (histidine solution) administered for 60 minutes as an intravenous infusion once weekly plus exemestane (25 mg) administered orally once daily"], "Eligibility": ["Incorporation criteria:", "Locally advanced or metastatic breast cancer", "- Histologically or cytologically confirmed ER+ and/or PgR+ and Her2 negative breast cancer", "- 18 years", "- Exclusion criteria:", "Has received prior treatment with exemestane", "A large visceral disease (rapidly progressive, life-threatening metastases, including symptomatic lymphangitic metastases)", "- Symptomatic CNS disease"], "Results": ["Performance measures:", "- Progression-free survival (PFS)", "In order to determine whether MM-121 + exemestane was more effective than placebo + exemestane in prolonging progression-free survival, PFS was a time to measure the event, and disease progression was defined using Criteria for Assessing Response to Solid Tumours (RECIST v1.1), \"such as a 20% increase in the sum of the longest diameter of the target lesions, or a measurable increase in non-target injury, or the appearance of new lesions.\" Progress-free survival was defined as the number of months between the date of randomization and the date of death or progression. If neither death nor progression were observed during the study, PFS data were censored during the last evaluation of the non-progressive tumour, unless the patient was stopped due to symptomatic deterioration.", "Delay: From the time of the first dose to the date of progression, the longest delay of 79.1 weeks", "Results 1:", "Title of arm/group: MM-121 + Exemestane", "Description of the arm/group: MM-121 (40mg/kg loading dose week 1, followed by 20 mg/kg per week) administered for 60 minutes as an intravenous infusion once a week plus exemestane (25 mg) administered orally once a day", "Total number of participants analysed: 56", "Median (95% confidence interval)", "Unit of measure: weeks 15.9 (9.3-30.3)", "Results 2:", "Title of the arm/group: Placebo + Exemestane", "Description of the arm/group: Placebo and Exemestane: Placebo (histidine solution) administered for 60 minutes as an intravenous infusion once a week plus exemestane (25 mg) administered orally once a day", "Total number of participants analysed: 59", "Median (95% confidence interval)", "Unit of measure: weeks 10.7 (8.1-16.1)"], "Adverse Events": ["Undesirable Events 1:", "Total: 7/56 (12.50 per cent)", "Febrile Neutropenia * 1/56 (1.79 %)", "Cardiovascular impairment * 1/56 (1.79%)", "Tachycardia * 0/56 (0.00 %)", "Abdominal pain (Upper) * 0/56 (0.00 %)", "Gastritis * 0/56 (0.00 %)", "Nausea * 2/56 (3.57%)", "Vomiting * 1/56 (1.79 %)", "Thoracic pain * 1/56 (1.79%)", "* 1/56 (1.79%)", "Pneumonia * 0/56 (0.00 %)", "Hepatic impairment * 2/56 (3.57%)", "Adverse Events 2:", "Total: 11/59 (18.64 per cent)", "Febrile Neutropenia * 0/59 (0.00 %)", "Cardiovascular impairment * 0/59 (0.00 %)", "* 1/59 (1.69%)", "Abdominal pain (Upper) * 1/59 (1.69%)", "Gastritis * 1/59 (1.69%)", "Nausea * 0/59 (0.00 %)", "Vomiting * 0/59 (0.00 %)", "Chest pain * 0/59 (0.00 %)", "* 1/59 (1.69%)", "Pneumonia * 1/59 (1.69%)", "Hepatic impairment * 0/59 (0.00 %)"]}